Structural basis for sialic acid-mediated self-recognition by complement factor H by Blaum BS et al.
 Newcastle University ePrints 
Blaum BS, Hannan JP, Herbert AP, Kavanagh D, Uhrin D, Stehle T. Structural 
basis for sialic acid-mediated self-recognition by complement factor H. 
Nature Chemical Biology 2015, 11(1), 77-82. 
Copyright: 
This is the author’s accepted manuscript of an article published in its final form by Nature Publishing 
Group, 2015. 
For the terms for reuse for this manuscript please see: 
http://www.nature.com/authors/policies/license.html 
Link to published article: http://dx.doi.org/10.1038/NCHEMBIO.1696 
Date deposited:  3rd February 2015 (made available 24th May 2015) 
ePrints – Newcastle University ePrints 
http://eprint.ncl.ac.uk 
 
1 
 
Structural basis for sialic acid-mediated self-recognition by complement factor H 
Bärbel S. Blaum
1*
, Jonathan P. Hannan
2
, Andrew P. Herbert
3
, David Kavanagh
4
, Dušan Uhrín
3
, Thilo 
Stehle
1,5 
 
1Interfaculty Institute of Biochemistry, University of Tübingen, Tübingen, Germany 
2Department of Medicine, University of Colorado School of Medicine, Aurora, Colorado, USA 
3The School of Chemistry, University of Edinburgh, West Mains Road, Edinburgh EH9 3JJ,U.K. 
4Institute of Genetic Medicine, International Centre for Life, Central Parkway, Newcastle upon Tyne, NE1 3BZ, U.K. 
5Department of Pediatrics, Vanderbilt University School of Medicine, Nashville, Tennessee, USA 
*to whom correspondence should be addressed: baerbel.blaum@uni-tuebingen.de 
 
Abstract 
The serum protein complement factor H (FH) ensures down-regulation of the complement alternative 1 
pathway, a branch of innate immunity, upon interaction with specific glycans on host cell-surfaces. 2 
Using ligand-based NMR, we screened a comprehensive set of sialylated glycans for binding to FH and 3 
solved the crystal structure of a ternary complex formed by the two C-terminal domains of FH, a 4 
sialylated trisaccharide, and the complement C3b thioester-containing domain (TED). Key residues in the 5 
sialic acid binding site are conserved from mice to men and residues linked to atypical hemolytic uremic 6 
syndrome (aHUS) cluster within this binding site, suggesting a possible role for sialic acid as host marker 7 
also in other mammals and a critical role in human renal complement homeostasis. Surprisingly, sialic 8 
acid binding to FH is structurally homologous to two evolutionary unrelated proteins. The crystal 9 
structure also advances our understanding of bacterial immune evasion strategies. 10 
 
 
 
2 
 
Introduction 
The ability to distinguish between host cells, pathogens, and altered host cells is the most fundamental 1 
property of the immune system. Adaptive immunity equips mammals for the encounter of an ever 2 
increasing number of rapidly evolving pathogens, while less specific but immediate defense carried out 3 
by the innate immune system. Adaptive and innate immunity are interwoven in the complement 4 
system1. Complement deficiencies can cause chronic disease or render vulnerable against infection with 5 
Gram-negative bacteria and certain viruses2–4. Inadvertent action of complement on host cells is 6 
prevented by dedicated regulatory proteins, some of which are expressed at the cell surface5. Pathogens 7 
frequently mimic or recruit complement regulators to escape host immunity6. 8 
The fluid-phase regulator factor H (FH) distinguishes cells that deserve protection from those that 9 
require elimination. FH is abundant in serum and is composed of twenty small, ellipsoidal domains of 10 
the complement control protein (CCP)/short consensus repeat (SCR) fold (see ref. 7 and references 11 
therein). FH accelerates the decay of the complement alternative pathway (AP) C3 convertase C3bBb, 12 
thus preventing local formation of more C3b, the central player of the complement amplification loop 13 
and a powerful opsonin. C3b is deposited on cells in a nonselective, irreversible manner via covalent 14 
attachment of its thioester-containing domain (TED) to cell-surface nucleophiles8. As a cofactor to the 15 
serine protease factor I, FH also regulates proteolytic degradation of already deposited C3b. FH-16 
mediated complement regulation is critical on host cells that do not possess additional, membrane-17 
bound regulators9 as well as on cells that do10. In order to confine C3b degradation to host cells, FH is 18 
thought to recognize specific host markers. Heterologous cells feature markers that may be structurally 19 
similar, conferring protection from complement to sheep erythrocytes and gram-negative bacteria11–13. 20 
Two classes of glycans are thought to act as genuine self-markers or molecular mimics of such: 21 
glycosaminoglycans (GAGs) and sialic acid glycans14. While binding of FH to GAGs is relatively well 22 
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understood15–17, the molecular details governing the interaction of FH with sialylated glycans have not 1 
been established. 2 
Sialic acids are nine-carbon pyranoses that cap the non-reducing end of glycan chains on human 3 
glycoproteins and gangliosides and mediate highly specific and diverse immunological recognition 4 
processes18,19. They feature various naturally occurring chemical modifications; prevalent in humans is α-5 
N-acetylneuraminic acid (Neu5Ac). Enzymatic removal of Neu5Ac turns non-activators of complement 6 
into activators11,12 as a consequence of reduced FH binding20. Sialylation contributes to complement 7 
evasion of pathogens such as Neisseria via recruitment of FH13. Since poly-sialic acid (formed by 8 
Neu5Acα2-8Neu5Acα repeats) does not regulate the FH affinity for C3b, it is likely that a larger specific 9 
epitope exists, encompassing an essential Neu5Ac moiety plus additional components20,21. It is not 10 
known whether FH binds simultaneously to cell-bound C3b and host markers, or whether sequential and 11 
perhaps even mutually exclusive binding to C3b and host glycans occurs22,23. 12 
We present a structural characterization of the low-affinity FH-Neu5Ac interaction at the molecular 13 
level. Our crystal structure of the FH C-terminal recognition domains in complex with a sialylated 14 
trisaccharide and the C3b TED suggest that C3b and sialylated glycans act in concert to target FH to host 15 
cell surfaces. Combination of our structural data with previous functional studies indicates that 16 
mutations in the CFH gene which predispose to atypical hemolytic uremic syndrome (aHUS) and are 17 
functionally impaired suffer from faulty sialic acid recognition. From the evolutionary point of view, the 18 
key amino acids in the FH sialic binding site are conserved across mammals. Unexpected structural 19 
homology with other sialic acid binding proteins that are not members of the CCP family hints to 20 
convergent evolution of a widespread sialic acid binding motif. 21 
Results 
Identification of sialic acid host glycans that bind FH 22 
The most common glycan caps in humans are Neu5Acα2-3Gal, Neu5Acα2-6Gal(NAc), and Neu5Acα2-23 
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8Neu5Ac24. We first tested representatives of these glycan types (Fig. 1) for binding to full-length FH in 1 
solution using saturation transfer difference (STD) NMR spectroscopy (Fig. 2). This technique is based on 2 
selective irradiation of protein protons and subsequent detection of magnetization transfer to small 3 
ligands with fast off-rates (above 100 Hz), allowing to detect weak affinity binding with Kd values of 1 µM 4 
and higher25,26. All glycans for which magnetization transfer from FH was observed contained the 3’sialyl 5 
lactose (3’SL, Neu5Acα2-3Galβ1-4Glc) trisaccharide (Fig. 1a-d). Binding was not prevented by several 6 
modifications of the lactose (Galβ1-4Glc) stem. These included an alternative glycosidic linkage (Galβ1-7 
3Glc, in disialyl lacto-N-tetraose, DSLNT, and in the GM1b and GM1 glycans), branching of the Gal ring 8 
(in the GM1 glycan), acetylation of the reducing end Glc (in the GM1b glycan and DSLNT), and branching 9 
of the Glc ring (in DSLNT). No glycans terminating in Neu5Acα2-6 or Neu5Acα2-8 bound FH (Fig. 1e-f, Fig. 10 
2). Resonances that can be unambiguously assigned in the 3’SL STD NMR spectrum are highlighted in 11 
Fig. 2. The strongest signal was observed for the Neu5Ac methyl group, suggesting that this group is a 12 
key component of the binding epitope. In contrast, both H3 protons received negligible saturation 13 
transfer. Other Neu5Ac proton resonances are located in the crowded spectral region between 3.5 ppm 14 
and 4.0 ppm where partial resonance overlap complicates the assignment, but peaks belonging to H5 15 
and H7 are distinct and were observed in the STD difference spectrum. Magnetization transfer was also 16 
observed for the Gal H1, H3, and H4 protons, all of which lie on one side of the Gal pyranose ring. 17 
Resonances for Gal H5 and Neu5Ac H4 overlap - one of these or both are also part of the binding 18 
epitope. For the Glc ring, only the β-anomer H1 and H2 can be clearly assigned in the difference 19 
spectrum. The NMR experiments establish Neu5Acα2-3Gal as the minimum epitope for the sialic acid-FH 20 
interaction and indicate that the dissociation constant for the complex is in the µM or mM range. Such 21 
low affinities are not unusual for glycan-protein complexes. 22 
To test if FH also binds 3’SL in the presence of other serum proteins, we performed a double-difference 23 
saturation transfer (STDD) NMR experiment using FH-depleted serum instead of buffer27. Serum 24 
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contains numerous proteins that bind Neu5Ac and are saturated along with FH in the selective 1 
irradiation step of the STD experiment. We therefore first collected a reference STD NMR spectrum of 2 
FH-depleted serum supplemented with 3’SL. Not surprisingly, some transfer to 3’SL from serum proteins 3 
other than FH was observed (Supplementary Results, Supplementary Fig. 1 online). We then repeated 4 
the experiment with a sample to which full length-FH was added. A comparison of both STDD spectra 5 
shows that additional saturation is transferred to 3’SL in the FH containing sample, suggesting that FH 6 
recognizes 3’SL also in the presence of other human serum proteins. The observed decrease of the STDD 7 
response may reflect competition of 3’SL with serum glycoproteins on which the 3’SLN glycan (3’sialyl-N-8 
acetyllactosamine, Neu5Acα2-3Galβ1-4GlcNAc) is abundant, as well as competition of FH with other 9 
serum proteins that bind 3’SL. 10 
Crystal structure of FH19-20 bound to C3d and 3’SL 11 
The sialic acid binding site in FH is likely located in its two most C-terminal domains13,28. STD NMR 12 
experiments were therefore also acquired with a recombinant construct comprising these domains 13 
(FH19-20). The STD spectra were very similar for full-length FH and FH19-20 (Supplementary Fig. 2 14 
online), indicating that domains 19 and 20 indeed mediate sialic acid binding. In the presence of both 15 
3’SL and 6’SL (6’ sialyl lactose, Neu5Acα2-6Galβ1-4Glc) all observed resonances could be attributed to 16 
3’SL (Supplementary Fig. 2 online), similar to what was observed for full-length FH. Next, FH19-20 and 17 
C3d (which corresponds to the cell-bound TED in C3b) were co-crystallized22 and a ternary complex was 18 
obtained by soaking with 3’SL (Supplementary Tables 1 and 2 online). Location, overall arrangement, 19 
and orientation of three crystallographic distinct 3’SL copies per asymmetric unit were essentially 20 
identical (Supplementary Fig. 3 and 4 online). One of the glycan binding sites did not participate in 21 
crystal contacts (chain F in the pdb), while in the other chains (D and E) the Glc exhibited crystal 22 
contacts. The Neu5Ac and Gal rings were not affected by crystal packing. 23 
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The Neu5Ac binding site is located in a recession between strand β3 and the hypervariable loop 1 
(residues 1182 to 1189) that forms one of the CCP-atypical lateral bulges in FH domain 20 (Fig. 2). A 2 
network of hydrogen bonds and salt bridges anchors the Neu5Ac ring to the surrounding protein side 3 
chains and backbone amides (Fig. 3a-d). The O8 and O9 hydroxyl groups of the glycerol chain are 4 
hydrogen-bonded to the backbone amide and carbonyl groups of E1198, respectively, and O9 forms 5 
another hydrogen bond with the W1183 backbone. The N-acetyl methyl group displays hydrophobic 6 
interactions with the side chains of residues L1181 and V1197, and furthermore with portions of the 7 
S1191 and E1195 side chains (Fig. 3a). The Neu5Ac amide group is hydrogen-bonded to the S1196 8 
backbone carbonyl atom and the O4 hydroxyl group to the E1195 side chain. The Neu5Ac carboxyl group 9 
forms a salt bridge with the side chain of R1215 (located in strand β4) and is coordinated by an ordered 10 
water molecule that is hydrogen-bonded to the S1196 amide. R1182, W1183, E1198, L1181 and F1199 11 
confine the glycerol chain to a narrow pocket (Fig. 3a and d). Perhaps the most striking feature of the 12 
binding site is the orientation of the W1183 indole ring, which packs against the 3’SL Gal and Glc rings 13 
(Fig. 3b). This interaction is an important determinant for the orientation of the 3’SL lactose stem. The 14 
Gal and Glc rings do not exhibit further interactions with the protein residues. This observation is in 15 
agreement with the NMR experiments, which show that modifications to the lactose stem can be 16 
accommodated. The strong Neu5Ac methyl peak and the observation of the Neu5Ac H4, H5, and H7 17 
protons in the 3’SL difference spectrum are in agreement with the glycan conformation observed in the 18 
crystal structure, and so is the Gal ring for which we observed magnetization transfer predominantly to 19 
the face that is oriented towards the protein in the crystal. 20 
To independently validate the observed interactions, two aHUS-associated CFH mutations were 21 
evaluated for FH Neu5Ac binding in STD NMR experiments with 3’SL, W1183R and R1215Q. No 22 
magnetization transfer was observed to either mutant, in agreement with the roles of the W1183 and 23 
R1215 side chains in coordination of 3’SL in our crystal structure (Supplementary Fig. 2 online). In total, 24 
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more than a dozen CFH mutations and single nucleotide polymorphisms that predispose to aHUS29 1 
affect residues that are located in or close to the sialic acid binding site of FH (Fig. 3c-d). 2 
The specificity of FH for sialylated glycans appears primarily determined by two factors: extensive and 3 
specific interactions with a single, non-reducing end Neu5Ac, and stacking interactions with the 4 
neighboring Gal. The latter interactions provide specificity for the α2-3 linkage as compounds with α2-6 5 
or α2-8 linked Neu5Ac are unlikely to form similar contacts. In a crystal structure of FH 19-20/C3d 6 
soaked with 40 mM 6’sialyl lactose (6’SL, ) only weak electron density for Neu5Ac and Gal was observed, 7 
indicating lower affinity. The Gal protruded further from the binding pocket and did not stack efficiently 8 
with the W1183 side chain. The situation would be even less favorable for the Neu5Acα2-8Neu5Acα 9 
disialyl cap. Notably, no magnetization transfer was observed to 6’SL or the Neu5Acα2-8 capped GD3 10 
oligosaccharide in STD NMR experiments (Fig. 2). 11 
A survey of the available crystallographic and NMR structures reveals that the FH domain 20 12 
hypervariable loop residues 1184-1188 are inherently flexible. They adopt different conformations in 13 
the context of different crystal contacts (see also Supplementary Fig. 4 online), lack electron density in 14 
the absence of such contacts, and display a significant drop in 1H, 15N-NOE values30. Although in close 15 
proximity to 3’SL in our complex structure, these residues do not interact directly with the glycan. A 16 
comparison with the unliganded FH19-20/C3d structure22 shows that glycan binding nevertheless 17 
rigidifies this loop. 18 
The ternary host recognition complex 19 
The C3d binding site in C-terminal FH involves mostly domain 19 and the inter-domain linker22,23, while 20 
the Neu5Ac binding site is contained entirely within domain 20. The two atoms that, in a physiological 21 
context, anchor both FH ligands to the cell surface (the Glc O1 in Neu5Ac and Cδ of C3d residue Q20, 22 
Q1013 in the pre-processed C3b) are 44 Å apart (Fig. 4, the 1013 side chain is displayed as glutamate as 23 
after reaction with a cell nucleophile). The C3b Q1013 side chain dictates the orientation that the FH C-24 
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terminal domains have to adopt in order to bind to cell-bound C3b. Both the Glc O1 and the C3b Q1013 1 
side chain must lay on the same face of the ternary complex if 3’SL is reflective of a cell surface 2 
sialoglycoconjugate that is simultaneously bound by FH. This orientation is observed in our crystal 3 
structure (Fig. 4) which therefore supports the existence of a ternary host recognition complex formed 4 
by cell-bound C3b, FH, and sialylated glycans. 5 
Cross-species conservation of the FH Neu5Ac binding site 6 
Cross-species conservation of the FH sialic acid binding site was assessed by sequence comparison of 7 
human FH with five other mammalian sequences (Supplementary Fig. 5 online). Identities ranged from 8 
98 % (chimpanzee) to 61 % (mouse) for the full-length protein. The amino acids that are most critical for 9 
sialic acid recognition, observed in our crystal structure, exhibit no or conservative mutations in all 10 
investigated sequences. W1183 and R1215 are strictly conserved. E1195 is subject to a conservative 11 
mutation in non-ape mammals. E1198, which may have a role in positioning the R1215 and W1183 side 12 
chains in the observed orientations, is also strictly conserved. R1182, stacking with the W1183 side 13 
chain, is conserved or subject to a conservative mutation. The hydrophobic base of the Neu5Ac binding 14 
site is also well-conserved: I1169, L1181, S1191, and F1199 are strictly conserved, and V1197 shows 15 
limited variation. 16 
AP activation upon Neu5Ac-removal depends on properdin 17 
We conducted competition experiments with Neu5Ac-containing glycans and multivalent 18 
neoglycoconjugates (3’SL and 6’SL coupled to serum ovalbumin). The hemolytic assay in which sheep 19 
erythrocytes (ES) are exposed to normal human serum with Mg-EGTA served as a platform for AP-20 
specific competition experiments. ES activate the human AP only after treatment with 21 
neuraminidase11,12. Direct competition with added sialic acid glycans or neoglycoconjugates at millimolar 22 
concentrations did not lead to increased cell lysis (data not shown). One possible explanation for this 23 
observation is that the high density of sialic acids on cell surfaces is critical for the low-affinity 24 
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interaction with FH and cannot be matched by soluble compounds. However, it is also possible that 1 
neuraminidase treated ES do not only loose FH binding but also recruit an AP activator. Recent reports 2 
revived the so-called Pillemer-model in which properdin serves as a direct AP activator31,32. 3 
Neuraminidase-treated ES were therefore exposed to properdin-depleted serum (Supplementary Fig. 6 4 
online). No lysis was observed in the absence of properdin, while supplementation with purified 5 
properdin resurrected cell lysis in a dose-dependent manner, suggesting that AP activity on erythrocytes 6 
is regulated by both FH and properdin. 7 
Discussion 
Our structural analysis of the FH-sialic acid interaction can be corroborated by past functional studies. 8 
These studies have found that the glycerol chain and carboxyl group of Neu5Ac are critical for FH 9 
recognition11,33,34 and that recognition is not determined by the presence of the Neu5Ac ring alone20,21. 10 
Our crystal structure and NMR as well as mutagenesis experiments are in agreement with these 11 
observations as both the glycerol chain and carboxyl group undergo directed interactions with residues 12 
in the FH binding site and the recognition is not independent of the Neu5Ac glycosidic linkage. 13 
Incorporation of the GM3 ganglioside protects liposomes from complement-mediated lysis35, and the 14 
3’SL used here is in fact identical with the GM3 glycan moiety. 15 
The crystal structure allows to rationalize known mutations that affect the FH C-terminal domain, 16 
predispose to aHUS29, and have been found to functionally impair FH36,37. Some mutations remove the 17 
most important interactions with 3’SL (W1183C/F/L/R, R1215G/Q), clash with the ligand (L1189F/P/R, 18 
S1191L/W, S1191L+V1197A double mutant), or disrupt the hydrophobic pocket into which the glycerol 19 
chain inserts (F1199S) (Fig 3). Others may affect positioning of the W1183 side chain (E1198A, R1182S, 20 
E1198K) or alter the Neu5Ac methyl group pocket (V1197A, I1169L38). T1184R and G1194D could alter 21 
the overall conformation of the binding site, although neither side chain directly coordinates Neu5Ac. 22 
In combination with the available biochemical data (erythrocyte neuraminidase treatment and 23 
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hemolytic assays), our findings suggest that 3’SL is a better proxy for erythrocytes than GAGs. 1 
Recombinant FH19-20 loses its capacity to lyse sensitized human erythrocytes via competition with full-2 
length FH after neuraminidase treatment of the cells39. FH6-8 and GAGs are the main determinants for 3 
FH host recognition in the human macula while the two C-terminal FH domains mediate recognition in 4 
the glomerulus, the kidney compartment affected by aHUS17. While GAGs play an important role for FH 5 
binding in the kidney, there must be additional host markers in this organ (but not in the eye)17. These 6 
findings, together with those presented here, provide strong evidence that sialic acid serves as a host 7 
marker in the glomerulus, imply distinct roles for sialic acid glycans and GAGs for complement regulation 8 
in the kidney, and indicate that sialic acid recognition is critical for aHUS predisposal. Sialic acid is 9 
abundant on the glomerular endothelium and necessary for glomerular integrity in mice models40. 10 
We would like to propose that the term ‘host polyanions’ to group GAGs and sialic acid glycans should 11 
be abandoned. Sulfated GAGs contain disaccharide repeats, adopt linear, helical structures41, are 12 
chemically inhomogeneous, and can have large molecular weights and numerous negative charges. In 13 
contrast, sialosides form comparably short sequences with often a single negative charge (the sialic acid 14 
carboxyl group), and can adopt branched structures. Our findings and past reports11,33,34 suggests that a 15 
specific recognition process rather than overall negative charge underlie FH binding to sialic acid, 16 
although the negative charge of the glycocalyx may well have a steering effect. We would like to suggest 17 
the terminology ‘glycan markers’ instead of ‘polyanion markers’ where both classes of FH glycan ligands 18 
are concerned. 19 
Infection with Streptococcus pneumonia can cause sporadic HUS, possibly due to bacterial 20 
neuraminidase activity and exposure of the Thomson-Friedenreich (TF) antigen (Galβ1-3GalNAc) to 21 
preformed IgM antibodies against this glycan42. In the light of our results, it is plausible that imbalanced 22 
regulation of complement after local reduction of FH binding may additionally contribute to the 23 
symptoms observed in pneumococcal HUS. 24 
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The FH19-20/3’SL complex further harbors implications for pathogenic immune evasion6. The outer 1 
surface protein E (OspE) of lyme disease causing Borrelia burgdorferi specifically binds to the FH C-2 
terminus44. Intriguingly, OspE binds FH via the W1183, S1196, E1198, and R1215 side chains that also 3 
provide the most important interaction for 3’SL38, assuring that FH bound to B. burgdorferi adopts an 4 
orientation that resembles its host cell orientation. The host marker binding sites in FH are also likely 5 
subject to evolutionary restrictions, an additional benefit for the FH-binding pathogens that bind to 6 
these sites. Certain Neisseria gonorrhoeae strains can modify their lipooligosaccharide layer to present 7 
an epitope similar to the human 3’SLN13. Thus, different bacteria have devised similar yet distinct 8 
mechanisms to capture FH: either using dedicated proteins that bind FH via its C-terminal sialic acid 9 
binding site or via direct glycan mimicry. 10 
Properdin initiates AP C3-convertase formation on rabbit erythrocytes (ER), activators of the AP 11 
independent of neuraminidase-treatment31. Our findings indicate that on non-activating surfaces such 12 
as ES, removal of sialic acid might not only decrease FH binding but, additionally, augment properdin 13 
binding. Both regulators may compete for binding to different cell surface types, independent of the 14 
mechanism by which properdin activates the AP. 15 
A comparison of the human FH sequence with other mammals revealed that key amino acids in the sialic 16 
acid binding site are conserved among different mammals, suggesting a possible role for sialic acid self-17 
recognition by FH also in non-hominid mammals. Notably, mice which transgenically express mouse FH 18 
without domains 17-20 spontaneously develop aHUS45. While the key residues are conserved there are 19 
non-conservative substitutions in proximate amino acids that do not directly interact with the Neu5Ac 20 
ring, for instance in the N-terminal part of the flexible loop (amino acids 1184-1186). These could 21 
modulate the relative sialoglycan binding affinities of individual FH variants somewhat, maybe reflecting 22 
species-specific variations in the sialic acid family. Human FH is insensitive to some but not all occurring 23 
variations of Neu5Ac33,34. As an innate immune regulator FH does not possess the adaptability of 24 
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complex adaptive immunity recognition molecules, it therefore seems plausible that FH evolution 1 
accounts for some variation in sialic acid type while keeping a firm grip on the overall glycan scaffold. It 2 
is conceivable that the many human FH relatives that display varying degrees of conservation in their 3 
glycan binding sites46 also act to modulate the relatively broad FH sialic acid (and also GAG) specificity. 4 
The Neu5Ac binding site in FH exhibits unexpected homology with human Siglecs (Sialic acid-binding 5 
immunoglobulin-type lectins)47 and a canine virus attachment protein48,49. In all three proteins, the 6 
Neu5Ac ring and glycerol chain align with an antiparallel β-sheet with β-sheet like interactions, while the 7 
Neu5Ac carboxyl group is coordinated by an arginine residue protruding from a neighboring strand 8 
(shown for FH in Fig. 3a). Given that the three proteins adopt different folds and have distinct biological 9 
functions it seems plausible that they converged to a common sialic acid binding mode and that further 10 
lectins with a homologous sialic acid binding site will be identified in the future. 11 
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Figures 
Figure 1: Chemical formulas of glycans tested in the STD NMR experiments with full-length FH. (a) 1 
3’sialyl lactose (3’SL, Neu5Acα2-3Galβ1-4Glc, R=OH) and 3’sialyl-N-acetyllactosamine (3’SLN, Neu5Acα2-2 
3Galβ1-4GlcNAc, R=NHAc), (b) GM1b glycan (Neu5Acα2-3Galβ1-3GalNAcβ1-4Galβ1-4Glc), (c) GM1 3 
glycan (Galβ1-3GalNAcβ1-4(Neu5Acα2-3)Galβ1-4Glc), (d) disialyl lacto-N-tetraose (DSLNT, Neu5Acα2-4 
3Galβ1-3(Neu5Acα2-6)GlcNAcβ1-3Galβ1-4Glc) (e) 6’sialyl lactose (6’SL, Neu5Acα2-6Galβ1-4Glc, R=OH) 5 
and 6’sialyl-N-acetyllactosamine (6’SLN, Neu5Acα2-6Galβ1-4GlcNAc, R=NHAc) (f) GD3 glycan 6 
(Neu5Acα2-8Neu5Acα2-3Galβ1-4Glc). 7 
Figure 2: FH binds α2-3 linked sialic acid glycans in its C-terminal domain. NMR reference spectra of 8 
pure glycan (top) and STD difference spectra with FH (bottom) using (a) 3’sialyl lactose (b) 6’sialyl 9 
lactose and (c) the GD3 glycan. Glycans are depicted schematically and select proton resonances are 10 
highlighted. Highlighted Glc resonances belong to the β-anomer. The Neu5Ac resonances are labeled 11 
‘3e’ for the H3 equatorial proton and ‘3a’ for the H3 axial proton. (d) Overall structure of FH19-20 12 
without ligand. (e) Enlarged view of domain 20 with bound 3’SL (cyan). A schematic display of the ligand 13 
reflects its orientation in the binding site. N- and C-terminus of the respective domains are labeled, and 14 
red coloring of residues 1182-1199 in domain 20 highlights the ligand binding site in panels d and e. 15 
Diagrams were generated with Topspin and PyMOL. 16 
Figure 3: The sialic acid FH binding site is a hotspot for aHUS mutations. (a) Enlargement of the sialic 17 
acid binding site with key amino acids highlighted (orange) and labeled. For clarity, only the sialic acid 18 
ring of 3’sialyl lactose is shown (cyan). Salt bridges and hydrogen bonds are shown as black dotted lines 19 
and a water molecule is displayed as a red sphere. (b) Rotated view of (a) with the full ligand (cyan) and 20 
only the W1183 side chain (orange) displayed. Inserted is the ligand in stick display with glycosidic 21 
linkages labeled. (c) and (d) Residues associated with aHUS shown in green. Wild type and disease-22 
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associated variants of each amino acid are listed. Residue L1181 is not disease-associated but shown 1 
(orange) for completeness of the glycerol chain hydrophobic interactions. 2 
Figure 4: Orientation of the ternary host recognition complex on cellular surfaces. (a) Superposition of 3 
the C3d/FH19-20/3’SL complex with C3b structure and schematic positioning on a cell surface. A C3d 4 
molecule of our ternary complex (chain B) was aligned with C3b TED (TED bluish grey, rest of C3b blue) 5 
in the published C3b structure (2I07.pdb8). FH19-20 and 3’SL are in red and cyan, respectively. The cell 6 
surface attachment points of the complex, the C3b residue 1013 (reacted to glutamate in 2I07.pdb and 7 
after attachment of cell surface hydoxy groups) and the 3’SL trisaccharide, are shown in stick 8 
representation. 9 
Online Methods 
Protein expression and purification. 10 
Proteins were purchased (full-length FH) from Complement Technology, Inc. or expressed recombinantly 11 
in E. coli (C3d) and Pichia pastoris (FH19-20). Expression and purification of the recombinantly expressed 12 
proteins is described elsewhere22,37. 13 
Glycans. 14 
Glycans were purchased from Carbosynth (3’SL(N) and 6’SL(N)) or Elicityl (GM1b glycan, GM1 glycan, 15 
GD3 glycan and DSLNT). Identity and purity of all glycans was assessed by 1H and 13C NMR spectroscopy 16 
of individual glycans resolved in pure D2O (Sigma Aldrich). In solution, the reducing end rings in 17 
oligosaccharides exchange between α- and β-anomeric forms, while their configurations are defined in 18 
the glycoconjugates which they decorate. Oligosaccharides used in this study are therefore denoted 19 
without stereo chemical specification for the reducing end ring throughout the text. 20 
NMR spectroscopy. 21 
NMR spectra were recorded at 288 K and 283 K using 3 mm tubes (200 μL sample volume) and a Bruker 22 
AVIII-600 spectrometer equipped with a room temperature probe head and processed with TOPSPIN 3.0 23 
15 
 
(Bruker). Samples for STD NMR spectra contained 2 mM of each of the different glycans (Carbosynth or 1 
Elicityl) and varying concentrations (10 uM ± 2 uM) of full-length FH (Complement Technology, Inc.) or 30 2 
uM of recombinant FH19-20. Proteins were buffer-exchanged prior to NMR experiments in 3 kDa MWCO 3 
centrifugal concentrators to 20 mM potassium phosphate pH 7.4, 150 mM NaCl in D2O. Glycan samples 4 
of the same concentration but with no protein present were used to verify that no direct excitation of 5 
the glycans took place during the on-resonance irradiation step of the STD pulse program. Off- and on-6 
resonance irradiation frequencies were set to -30 ppm and 7.3 ppm, respectively. The irradiation power 7 
of the selective pulses was 57 Hz, the saturation time was 2 s, and the total relaxation delay was 3 s. A 50 8 
ms continuous-wave spin-lock pulse with a strength of 3.2 kHz was employed to suppress residual 9 
protein signals. A total number of 512 scans were recorded. A total of 10,000 points were collected, and 10 
spectra were multiplied with a Gaussian window function prior to Fourier transformation. Spectra were 11 
referenced to 298 K using the α-D-Glc anomeric proton as an internal standard50. For the double-12 
difference saturation experiment with serum proteins, 0.8 mL FH-depleted human serum (Complement 13 
Technology, Inc.) was concentrated to 0.4 mL in a 10 kDa MWCO centrifugal concentrator. The 14 
concentrated serum was diluted to 4 mL with 20 mM potassium phosphate pH 7.4 with 150 mM NaCl in 15 
D2O, supplemented with a 1 M EDTA stock to a final EDTA concentration of 20 mM, and concentrated 16 
again to 0.4 mL, then split in two. 250 ug FH was added to one of the samples, yielding a concentration 17 
of 8 uM fl-FH, and both samples were buffer-exchanged 3 times using the D2O buffer without EDTA. 18 
These buffer exchange steps served to remove small molecules from the serum and to exchange H2O 19 
against D2O since no water suppression was used in the STD NMR spectra in order not to suppress the 20 
glycan anomeric proton resonances. STD NMR spectra were collected with the aforementioned 21 
parameters on both samples before and after addition of 3 mM 3'SL. Difference spectra obtained 22 
without 3'SL were subtracted from difference spectra obtained with 3'SL in both cases to yield double-23 
difference saturation transfer (STDD) spectra of twofold concentrated serum proteins with 3'SL and no 24 
16 
 
FH, and with both 3'SL and FH. 1 
Crystallography. 2 
Co-crystals of FH19-20 and C3d were grown at 20 °C by hanging drop vapor diffusion essentially as 3 
described22. Crystals were transferred into a 40 mM 3’SL soaking solution prepared from 1 uL of a 400 4 
mM 3’SL stock (in 20 mM Tris-HCl pH 7.0, 50 mM NaCl) and 9 uL reservoir solution (0.1 M Tris-HCl pH 5 
9.0, 8 % (w/v) PEG 8K), stepwise cryo-protected with 20 % (v/v) glycerol in reservoir solution after 20 6 
min of glycan soaking, and flash-frozen in liquid nitrogen. 3600 diffraction images with 0.1°/frame were 7 
collected at the X06DA beamline of the Swiss Light Source in Villingen, Switzerland, and processed with 8 
XDS51. 9 
Model building. 10 
The native FH19-20/C3d complex structure22 was used for initial refinement against the newly collected 11 
data in REFMAC52. Difference density maps revealed unambiguous electron density for the 12 
oligosaccharide in all three copies of FH 20. Water molecules were removed, the ligand was placed 13 
manually in the difference map, and the model went through several cycles of real-space refinement in 14 
COOT53 and restrained reciprocal refinement using REFMAC. After the final refinement step, all 3’SL  15 
molecules were removed from the model and an unbiased omit map was produced in PHENIX54 using 16 
the default parameters for simulated annealing. Model quality was assessed using MolProbity55 and the 17 
Carbohydrate Structure Suite56. 18 
Protein sequence alignment. 19 
FH19-20 protein sequences from other mammals were identified using a BLAST search with the human 20 
FH database entry (Uniprot P08603). The sequences of chimpanzee, orangutan, rabbit, horse, cow, and 21 
mouse were aligned with the human FH sequence using COBALT57. The sheep sequence was not used 22 
because all sheep FH entries in the database are denoted ‘fragment’, with domain 20 missing 23 
Hemolytic assay. 24 
17 
 
Sheep erythrocytes were obtained from defibrinated sheep blood (TCS Biosciences), properdin and 1 
properdin-depleted serum were obtained from Complement Technologies Inc. 1 mL of sheep blood was 2 
diluted with 10 ml cold buffer 1 (20 mM HEPES, 145 mM NaCl, 0.1 % (w/v) gelatin (from pork skin, Fluka) 3 
and 10 mM EDTA, pH 7.3 at 25 °C). The cell suspension was mixed gently and spun for 10 min at 500 X g, 4 
at 4 °C. The supernatant and a layer of leucocytes were aspirated off and the procedure was repeated 5 
two more times with buffer 1 and subsequently three times with an identical buffer without EDTA but 6 
with 5 mM MgCl2 and with 5 mM EGTA (buffer 2). Thus obtained cells were treated with neuraminidase 7 
from Clostridium perfringens (New England Biolabs) as follows: roughly 6 x 109 cells were resuspended in 8 
a total reaction volume of 100 μL using buffer 1 without EDTA and 500 units of neuraminidase, and the 9 
reaction was incubated for 30 min at 37 °C. Subsequently, 150 μL of buffer 2 was added and the cells 10 
were spun for 1 min at 500 g, at 4°C. The supernatant was removed and the washing step repeated two 11 
more times. For the hemolytic assay, approximately 2.3 x 108 neuraminidase-treated cells and cells that 12 
were treated identically except for the omission of neuraminidase were used. The cells were mixed with 13 
20 μL of human serum (intact, heat-inactivated at 56 °C for 30 min, or properdin-depleted) and buffer 2 14 
and/or properdin to give an reaction volume of 40 μL. The reaction was incubated for 20 min at 37 °C, 15 
stopped by addition of 150 μL cold buffer 1 without gelatin, and spun at 1500 g for 5 min at 4°C. Lysis 16 
was determined by measuring the absorbance of the supernatant at 415 nm (A415) and compared to 17 
the A415 value for the same amount of cells lysed with pure water. 18 
Accession codes. Protein Data Bank: Coordinates and structure factors for the FH19-20/C3d/3’SL 19 
complex were deposited under the accession number 4ONT. 20 
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